Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial - Endpoints News

Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial – Endpoints News

9 February 2026

Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial Endpoints News
Roche unveils data behind BTK inhibitor’s phase 3 multiple sclerosis win in Ocrevus trial Fierce Biotech
RO: Fenebrutinib matched ocrelizumab in PPMS efficacy and offers a promising oral high-efficacy MS option TradingView
Roche’s multiple sclerosis drug fenebrutinib meets goal in late-stage trial ET Pharma
ACTRIMS 2026: Fenebrutinib matches Ocrevus in PPMS trial Multiple Sclerosis News Today